Advertisement
CGEN or EDAP or NXTC
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CGEN’s FA Score shows that 1 FA rating(s) are green whileEDAP’s FA Score has 0 green FA rating(s), and NXTC’s FA Score reflects 0 green FA rating(s).
- CGEN’s FA Score: 1 green, 4 red.
- EDAP’s FA Score: 0 green, 5 red.
- NXTC’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CGEN’s TA Score shows that 5 TA indicator(s) are bullish while EDAP’s TA Score has 5 bullish TA indicator(s), and NXTC’s TA Score reflects 2 bullish TA indicator(s).
- CGEN’s TA Score: 5 bullish, 5 bearish.
- EDAP’s TA Score: 5 bullish, 3 bearish.
- NXTC’s TA Score: 2 bullish, 4 bearish.
Price Growth
CGEN (@Biotechnology) experienced а -4.00% price change this week, while EDAP (@Medical Distributors) price change was +6.25% , and NXTC (@Biotechnology) price fluctuated -22.88% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.97%. For the same industry, the average monthly price growth was +11.13%, and the average quarterly price growth was +63.98%.
The average weekly price growth across all stocks in the @Medical Distributors industry was +2.32%. For the same industry, the average monthly price growth was +3.71%, and the average quarterly price growth was +9.17%.
Reported Earning Dates
CGEN is expected to report earnings on Nov 06, 2025.
EDAP is expected to report earnings on Nov 06, 2025.
NXTC is expected to report earnings on Oct 30, 2025.
Industries' Descriptions
@Biotechnology (+0.97% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical Distributors (+2.32% weekly)Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
| CGEN | EDAP | NXTC | |
| Capitalization | 159M | 89M | 24.6M |
| EBITDA | -19.81M | -19.3M | -61.2M |
| Gain YTD | 17.647 | 7.692 | -0.562 |
| P/E Ratio | 64.00 | N/A | N/A |
| Revenue | 22.1M | 63M | 0 |
| Total Cash | 93.9M | 16.3M | 35.3M |
| Total Debt | 2.97M | 8.96M | 4.67M |
CGEN | EDAP | NXTC | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 20 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | 50 Fair valued | 50 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 46 | 42 | 37 | |
P/E GROWTH RATING 1..100 | 22 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CGEN's Valuation (50) in the Biotechnology industry is in the same range as EDAP (50) and is in the same range as NXTC (50). This means that CGEN's stock grew similarly to EDAP’s and similarly to NXTC’s over the last 12 months.
CGEN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDAP (100) and is in the same range as NXTC (100). This means that CGEN's stock grew similarly to EDAP’s and similarly to NXTC’s over the last 12 months.
CGEN's SMR Rating (97) in the Biotechnology industry is in the same range as EDAP (98) and is in the same range as NXTC (100). This means that CGEN's stock grew similarly to EDAP’s and similarly to NXTC’s over the last 12 months.
NXTC's Price Growth Rating (37) in the Biotechnology industry is in the same range as EDAP (42) and is in the same range as CGEN (46). This means that NXTC's stock grew similarly to EDAP’s and similarly to CGEN’s over the last 12 months.
CGEN's P/E Growth Rating (22) in the Biotechnology industry is significantly better than the same rating for NXTC (100) and is significantly better than the same rating for EDAP (100). This means that CGEN's stock grew significantly faster than NXTC’s and significantly faster than EDAP’s over the last 12 months.
| CGEN | EDAP | NXTC | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 88% | N/A | 2 days ago 83% |
| Stochastic ODDS (%) | 2 days ago 77% | 2 days ago 69% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 89% | 2 days ago 74% | N/A |
| MACD ODDS (%) | 2 days ago 85% | 2 days ago 65% | N/A |
| TrendWeek ODDS (%) | 2 days ago 89% | 2 days ago 73% | 2 days ago 84% |
| TrendMonth ODDS (%) | 2 days ago 79% | 2 days ago 85% | 2 days ago 80% |
| Advances ODDS (%) | 17 days ago 80% | 11 days ago 74% | 9 days ago 76% |
| Declines ODDS (%) | 3 days ago 90% | 9 days ago 84% | 3 days ago 83% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 72% | 2 days ago 86% |
| Aroon ODDS (%) | 2 days ago 75% | 2 days ago 83% | 2 days ago 90% |
Advertisement
EDAP and
Correlation & Price change
A.I.dvisor tells us that EDAP and AORT have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EDAP and AORT's prices will move in lockstep.
| Ticker / NAME | Correlation To EDAP | 1D Price Change % | ||
|---|---|---|---|---|
| EDAP | 100% | -0.83% | ||
| AORT - EDAP | 29% Poorly correlated | N/A | ||
| AVNS - EDAP | 21% Poorly correlated | N/A | ||
| SRDX - EDAP | 21% Poorly correlated | -0.87% | ||
| UFPT - EDAP | 20% Poorly correlated | +0.39% | ||
| SENS - EDAP | 20% Poorly correlated | -4.63% | ||
More | ||||